Click here to get full coverage on Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability  simplywall.st

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st

Click here to get full coverage on Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - Yahoo Finance

Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely?  Yahoo Finance

Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - Yahoo Finance

Click here to get full coverage on Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform - Seeking Alpha

Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform  Seeking Alpha

Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform - Seeking Alpha

Click here to get full coverage on Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages  MarketBeat

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on $TNYA stock is down 12% today. Here's what we see in our data. - Quiver Quantitative

$TNYA stock is down 12% today. Here's what we see in our data.  Quiver Quantitative

$TNYA stock is down 12% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial - MSN

FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial  MSN

FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial - MSN

Click here to get full coverage on Tenaya (NASDAQ: TNYA) presents TN-201 MyPEAK-1 interim data in AHA late-breaking session - Stock Titan

Tenaya (NASDAQ: TNYA) presents TN-201 MyPEAK-1 interim data in AHA late-breaking session  Stock Titan

Tenaya (NASDAQ: TNYA) presents TN-201 MyPEAK-1 interim data in AHA late-breaking session - Stock Titan

Click here to get full coverage on Tenaya Therapeutics (TNYA): Evaluating Valuation After Investor Buzz on MyPEAK-1 and RIDGE-1 Clinical Updates - Yahoo Finance

Tenaya Therapeutics (TNYA): Evaluating Valuation After Investor Buzz on MyPEAK-1 and RIDGE-1 Clinical Updates  Yahoo Finance

Tenaya Therapeutics (TNYA): Evaluating Valuation After Investor Buzz on MyPEAK-1 and RIDGE-1 Clinical Updates - Yahoo Finance

Click here to get full coverage on 202,000 Shares at $1.20: Tenaya Therapeutics Grants Inducement Stock Options to New Employees - Stock Titan

202,000 Shares at $1.20: Tenaya Therapeutics Grants Inducement Stock Options to New Employees  Stock Titan

202,000 Shares at $1.20: Tenaya Therapeutics Grants Inducement Stock Options to New Employees - Stock Titan

Click here to get full coverage on Can Tenaya Therapeutics’ Leadership Messaging Shape Long-Term Perceptions and Value Creation for TNYA? - Yahoo Finance

Can Tenaya Therapeutics’ Leadership Messaging Shape Long-Term Perceptions and Value Creation for TNYA?  Yahoo Finance

Can Tenaya Therapeutics’ Leadership Messaging Shape Long-Term Perceptions and Value Creation for TNYA? - Yahoo Finance

Click here to get full coverage on Tenaya Therapeutics (TNYA): Assessing Valuation Ahead of Key Genetic Medicines Conference Presentation - simplywall.st

Tenaya Therapeutics (TNYA): Assessing Valuation Ahead of Key Genetic Medicines Conference Presentation  simplywall.st

Tenaya Therapeutics (TNYA): Assessing Valuation Ahead of Key Genetic Medicines Conference Presentation - simplywall.st

Click here to get full coverage on Tenaya Therapeutics Stock (TNYA) Opinions on CEO Conference Appearances - Quiver Quantitative

Tenaya Therapeutics Stock (TNYA) Opinions on CEO Conference Appearances  Quiver Quantitative

Tenaya Therapeutics Stock (TNYA) Opinions on CEO Conference Appearances - Quiver Quantitative

Click here to get full coverage on We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate - Yahoo Finance

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate  Yahoo Finance

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate - Yahoo Finance

Click here to get full coverage on Will Tenaya Therapeutics' (TNYA) Conference Spotlight Strengthen Confidence in Its Genetic Medicine Pipeline? - simplywall.st

Will Tenaya Therapeutics' (TNYA) Conference Spotlight Strengthen Confidence in Its Genetic Medicine Pipeline?  simplywall.st

Will Tenaya Therapeutics' (TNYA) Conference Spotlight Strengthen Confidence in Its Genetic Medicine Pipeline? - simplywall.st

Click here to get full coverage on New Analyst Forecast: $TNYA Given $9.0 Price Target - Quiver Quantitative

New Analyst Forecast: $TNYA Given $9.0 Price Target  Quiver Quantitative

New Analyst Forecast: $TNYA Given $9.0 Price Target - Quiver Quantitative

Click here to get full coverage on Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - simplywall.st

Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely?  simplywall.st

Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - simplywall.st

Click here to get full coverage on $TNYA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

$TNYA stock is up 7% today. Here's what we see in our data.  Quiver Quantitative

$TNYA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Tenaya (NASDAQ: TNYA) reports TN-201 interim data: troponin I down 74%, MyBP-C up 14% - Stock Titan

Tenaya (NASDAQ: TNYA) reports TN-201 interim data: troponin I down 74%, MyBP-C up 14%  Stock Titan

Tenaya (NASDAQ: TNYA) reports TN-201 interim data: troponin I down 74%, MyBP-C up 14% - Stock Titan

Click here to get full coverage on Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) market cap surged US$12m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) market cap surged US$12m last week, private equity firms who have a lot riding on the company were rewarded  simplywall.st

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) market cap surged US$12m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st

Click here to get full coverage on New Analyst Forecast: $TNYA Given $5.0 Price Target | TNYA Stock News - Quiver Quantitative

New Analyst Forecast: $TNYA Given $5.0 Price Target | TNYA Stock News  Quiver Quantitative

New Analyst Forecast: $TNYA Given $5.0 Price Target | TNYA Stock News - Quiver Quantitative

Click here to get full coverage on $TNYA stock is up 19% today. Here's what we see in our data. - Quiver Quantitative

$TNYA stock is up 19% today. Here's what we see in our data.  Quiver Quantitative

$TNYA stock is up 19% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on William Blair Analysts Raise Earnings Estimates for TNYA - MarketBeat

William Blair Analysts Raise Earnings Estimates for TNYA  MarketBeat

William Blair Analysts Raise Earnings Estimates for TNYA - MarketBeat

Click here to get full coverage on Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Wednesday  MarketBeat

Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Click here to get full coverage on Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - Yahoo Finance

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?  Yahoo Finance

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - Yahoo Finance

Click here to get full coverage on Fireside chat Oct 14: Tenaya Therapeutics CEO Faraz Ali at H.C. Wainwright; 1x1 meetings Oct 15, replay 30 days - Stock Titan

Fireside chat Oct 14: Tenaya Therapeutics CEO Faraz Ali at H.C. Wainwright; 1x1 meetings Oct 15, replay 30 days  Stock Titan

Fireside chat Oct 14: Tenaya Therapeutics CEO Faraz Ali at H.C. Wainwright; 1x1 meetings Oct 15, replay 30 days - Stock Titan

Click here to get full coverage on Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy  Yahoo Finance

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance

Click here to get full coverage on Tenaya therapeutics CMO Tingley sells $3826 in stock - Investing.com

Tenaya therapeutics CMO Tingley sells $3826 in stock  Investing.com

Tenaya therapeutics CMO Tingley sells $3826 in stock - Investing.com

Click here to get full coverage on FDA pauses Tenaya’s TN-201 trial; company sees no timeline impact - Stock Titan

FDA pauses Tenaya’s TN-201 trial; company sees no timeline impact  Stock Titan

FDA pauses Tenaya’s TN-201 trial; company sees no timeline impact - Stock Titan

Click here to get full coverage on Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March  Yahoo Finance

Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Click here to get full coverage on Tenaya's Gene Therapies Clear Key Safety Hurdles: Q4 Data Readouts Coming for Heart Disease Treatments - Stock Titan

Tenaya's Gene Therapies Clear Key Safety Hurdles: Q4 Data Readouts Coming for Heart Disease Treatments  Stock Titan

Tenaya's Gene Therapies Clear Key Safety Hurdles: Q4 Data Readouts Coming for Heart Disease Treatments - Stock Titan

Click here to get full coverage on Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update  Yahoo Finance

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Click here to get full coverage on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average Target Price from Brokerages - MarketBeat

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average Target Price from Brokerages  MarketBeat

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average Target Price from Brokerages - MarketBeat

Click here to get full coverage on Tenaya Therapeutics (NASDAQ:TNYA) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat

Tenaya Therapeutics (NASDAQ:TNYA) Earns Sell (D-) Rating from Weiss Ratings  MarketBeat

Tenaya Therapeutics (NASDAQ:TNYA) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat

Click here to get full coverage on Tenaya Therapeutics Grants Stock Options to New Employees as Part of Employment Offer - Quiver Quantitative

Tenaya Therapeutics Grants Stock Options to New Employees as Part of Employment Offer  Quiver Quantitative

Tenaya Therapeutics Grants Stock Options to New Employees as Part of Employment Offer - Quiver Quantitative

Click here to get full coverage on Tenaya Therapeutics: Is Gene Therapy the Future? - StocksToTrade

Tenaya Therapeutics: Is Gene Therapy the Future?  StocksToTrade

Tenaya Therapeutics: Is Gene Therapy the Future? - StocksToTrade

Click here to get full coverage on Tenaya Therapeutics to Present Interim Results from MyPEAK-1 Clinical Trial at AHA 2025 Scientific Sessions - Quiver Quantitative

Tenaya Therapeutics to Present Interim Results from MyPEAK-1 Clinical Trial at AHA 2025 Scientific Sessions  Quiver Quantitative

Tenaya Therapeutics to Present Interim Results from MyPEAK-1 Clinical Trial at AHA 2025 Scientific Sessions - Quiver Quantitative

Click here to get full coverage on Tenaya Therapeutics CEO Faraz Ali to Speak at Upcoming Investor and Industry Conferences in October 2025 - Quiver Quantitative

Tenaya Therapeutics CEO Faraz Ali to Speak at Upcoming Investor and Industry Conferences in October 2025  Quiver Quantitative

Tenaya Therapeutics CEO Faraz Ali to Speak at Upcoming Investor and Industry Conferences in October 2025 - Quiver Quantitative

Click here to get full coverage on Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st

Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA)  simplywall.st

Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st

Click here to get full coverage on Tenaya Therapeutics (TNYA) Retains 'Buy' Rating with $9 Target P - GuruFocus

Tenaya Therapeutics (TNYA) Retains 'Buy' Rating with $9 Target P  GuruFocus

Tenaya Therapeutics (TNYA) Retains 'Buy' Rating with $9 Target P - GuruFocus

Click here to get full coverage on Chardan Capital Issues Optimistic Forecast for TNYA Earnings - MarketBeat

Chardan Capital Issues Optimistic Forecast for TNYA Earnings  MarketBeat

Chardan Capital Issues Optimistic Forecast for TNYA Earnings - MarketBeat

Click here to get full coverage on Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial - Seeking Alpha

Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial  Seeking Alpha

Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial - Seeking Alpha

Click here to get full coverage on Tenaya Therapeutics Surges Forward: What’s Next? - StocksToTrade

Tenaya Therapeutics Surges Forward: What’s Next?  StocksToTrade

Tenaya Therapeutics Surges Forward: What’s Next? - StocksToTrade

Click here to get full coverage on Tenaya Therapeutics Presents Promising Interim Clinical - GlobeNewswire

Tenaya Therapeutics Presents Promising Interim Clinical  GlobeNewswire

Tenaya Therapeutics Presents Promising Interim Clinical - GlobeNewswire

Click here to get full coverage on 93% of Young Heart Disease Patients Have No Treatment Options: Landmark Tenaya Study of 213 Children - Stock Titan

93% of Young Heart Disease Patients Have No Treatment Options: Landmark Tenaya Study of 213 Children  Stock Titan

93% of Young Heart Disease Patients Have No Treatment Options: Landmark Tenaya Study of 213 Children - Stock Titan

Click here to get full coverage on Tenaya Therapeutics Sees Potential Market Upsurge Amid Strategic Moves - timothysykes.com

Tenaya Therapeutics Sees Potential Market Upsurge Amid Strategic Moves  timothysykes.com

Tenaya Therapeutics Sees Potential Market Upsurge Amid Strategic Moves - timothysykes.com

Click here to get full coverage on Tenaya Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview - TradingView

Tenaya Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview  TradingView

Tenaya Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview - TradingView

Click here to get full coverage on What is Lifesci Capital's Estimate for TNYA FY2025 Earnings? - MarketBeat

What is Lifesci Capital's Estimate for TNYA FY2025 Earnings?  MarketBeat

What is Lifesci Capital's Estimate for TNYA FY2025 Earnings? - MarketBeat

Click here to get full coverage on Tenaya Therapeutics’ Stocks Soar: Right Time to Buy? - StocksToTrade

Tenaya Therapeutics’ Stocks Soar: Right Time to Buy?  StocksToTrade

Tenaya Therapeutics’ Stocks Soar: Right Time to Buy? - StocksToTrade

Click here to get full coverage on Tenaya therapeutics CEO Ali Faraz sells $4,157 in stock By Investing.com - Investing.com Nigeria

Tenaya therapeutics CEO Ali Faraz sells $4,157 in stock By Investing.com  Investing.com Nigeria

Tenaya therapeutics CEO Ali Faraz sells $4,157 in stock By Investing.com - Investing.com Nigeria

Click here to get full coverage on Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update  GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Click here to get full coverage on Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - GlobeNewswire

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference  GlobeNewswire

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - GlobeNewswire

Click here to get full coverage on Tenaya: Two Heart Disorder Data Releases Q4 2025 Brings About Major Inflection Point - Seeking Alpha

Tenaya: Two Heart Disorder Data Releases Q4 2025 Brings About Major Inflection Point  Seeking Alpha

Tenaya: Two Heart Disorder Data Releases Q4 2025 Brings About Major Inflection Point - Seeking Alpha

Click here to get full coverage on Tenaya's $52.5M Offering: What Does This Massive 75M Share Dilution Mean for TNYA Investors? - Stock Titan

Tenaya's $52.5M Offering: What Does This Massive 75M Share Dilution Mean for TNYA Investors?  Stock Titan

Tenaya's $52.5M Offering: What Does This Massive 75M Share Dilution Mean for TNYA Investors? - Stock Titan

Click here to get full coverage on Tenaya Therapeutics faces Nasdaq delisting over share price - Investing.com

Tenaya Therapeutics faces Nasdaq delisting over share price  Investing.com

Tenaya Therapeutics faces Nasdaq delisting over share price - Investing.com

Click here to get full coverage on Tenaya Therapeutics SVP, finance Higa sells $1.8k in stock - Investing.com

Tenaya Therapeutics SVP, finance Higa sells $1.8k in stock  Investing.com

Tenaya Therapeutics SVP, finance Higa sells $1.8k in stock - Investing.com

Click here to get full coverage on $TNYA stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

$TNYA stock is up 14% today. Here's what we see in our data.  Quiver Quantitative

$TNYA stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Tenaya therapeutics CMO Tingley sells $6.3k in shares - Investing.com

Tenaya therapeutics CMO Tingley sells $6.3k in shares  Investing.com

Tenaya therapeutics CMO Tingley sells $6.3k in shares - Investing.com

Click here to get full coverage on TNYA: Gene therapy programs advance with positive data; net loss narrows and cash runway extends into 2026 - TradingView

TNYA: Gene therapy programs advance with positive data; net loss narrows and cash runway extends into 2026  TradingView

TNYA: Gene therapy programs advance with positive data; net loss narrows and cash runway extends into 2026 - TradingView

Click here to get full coverage on Tenaya (TNYA) Q2 Loss Narrows 59% - The Globe and Mail

Tenaya (TNYA) Q2 Loss Narrows 59%  The Globe and Mail

Tenaya (TNYA) Q2 Loss Narrows 59% - The Globe and Mail

Click here to get full coverage on Tenaya Therapeutics Reports Improved Financials Amid Strategic Focus - TipRanks

Tenaya Therapeutics Reports Improved Financials Amid Strategic Focus  TipRanks

Tenaya Therapeutics Reports Improved Financials Amid Strategic Focus - TipRanks

Click here to get full coverage on Tenaya Therapeutics Completes Enrollment in MyPEAK™-1 and RIDGE™-1 Trials for TN-201 and TN-401, Reports Positive Safety Reviews and Cash Runway Into 2026 - Quiver Quantitative

Tenaya Therapeutics Completes Enrollment in MyPEAK™-1 and RIDGE™-1 Trials for TN-201 and TN-401, Reports Positive Safety Reviews and Cash Runway Into 2026  Quiver Quantitative

Tenaya Therapeutics Completes Enrollment in MyPEAK™-1 and RIDGE™-1 Trials for TN-201 and TN-401, Reports Positive Safety Reviews and Cash Runway Into 2026 - Quiver Quantitative

Click here to get full coverage on FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial - TipRanks

FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial  TipRanks

FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial - TipRanks

Click here to get full coverage on Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 - GlobeNewswire

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025  GlobeNewswire

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 - GlobeNewswire

Click here to get full coverage on Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update  Yahoo Finance

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Click here to get full coverage on Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge - InflaRx (NASDAQ:IFRX), Alector (NASDAQ:ALEC) - Benzinga

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge - InflaRx (NASDAQ:IFRX), Alector (NASDAQ:ALEC)  Benzinga

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge - InflaRx (NASDAQ:IFRX), Alector (NASDAQ:ALEC) - Benzinga

Click here to get full coverage on CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛

CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $6  富途牛牛

TNYA

Price Chart

Key Statistics

Technicals

About TNYA

Latest News

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st

Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - Yahoo Finance

Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform - Seeking Alpha

Advanced Charts

Top Gainers

Top Losers